Annual Report 2003 Aventis - Sanofi

Aventis Strategic Brands
Lantus (insulin glargine) is the world’s
fi rst long-acting insulin analogue that
provides 24-hour insulin coverage
through a once-daily injection with
no pronounced peak of action.
Approved indications
- Once-daily subcutaneous administration
in the treatment of adult patients
with type 2 diabetes mellitus who
require basal (long-acting) insulin for the
control of hyperglycemia and for adult
and pediatric (age six and older) patients
with type 1 diabetes mellitus
- Flexible dosing, i.e. at any time of the
day, in patients with types 1 and 2 diabetes
mellitus (U.S. / EU)
Major markets
Approved worldwide, Lantus is the most
frequently prescribed medication for
newly diagnosed type 1 cases in the U.S.
and Germany. The global roll-out continued
in 2003, with launches taking place
in over 40 countries, including France
and Japan.
Product features
- Lantus is the only once-daily insulin
analogue that is proven to lower basal
glucose levels for a full 24 hours
- Delivers excellent basal glucose control
in combination with oral hypoglycemic
agents or as part of a regimen with
short-acting regular insulin
>> 19